 |
Colfosceril palmitate, cetyl alcohol, tyloxapol |
|---|---|
| Trade Name | Exosurf Neonatal For Intratracheal Suspension |
| Orphan Indication | Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less |
| USA Market Approval | USA |
| USA Designation Date | 1989-10-20 00:00:00 |
| Sponsor | Glaxo Wellcome Inc.;5 Moore Drive;Research Triangle Park, NC, 27709 |
